Sparrow Pharmaceuticals will build better corticosteroid drugs (e.g. prednisone) with a 2nd drug that reduces side effects and maintains efficacy. SPI-99, to prevent ophthalmic corticosteroid-induced glaucoma, inhibited glaucomatous effects of cortisone in a model system, and was well tolerated in its first clinical trial. SPI-86, to reduce metabolic effects (diabetes, hepatic steatosis, weight gain) associated with oral corticosteroid use, has a wide therapeutic index based on completed preclinical safety testing. In partnership with HiFiBiO, Sparrow Pharmaceuticals will develop the first therapeutic antibody to treat depression and PTSD.